Preparation of PEOz-modified single-walled carbon nanotube paclitaxel delivery system and evaluation of its anti-tumor effect in vitro
10.7501/j.issn.0253-2670.2020.03.009
- Author:
Xiao-Ning WANG
1
Author Information
1. College of Pharmacy, Xi'an Medical University
- Publication Type:Journal Article
- Keywords:
Anti-tumor;
Biocompatibility;
Dialysis method;
Hemolysis test;
Paclitaxel;
PH responsivity;
Poly(2-ethyl-2-oxazoline);
Single-walled carbon nanotube drug delivery system
- From:
Chinese Traditional and Herbal Drugs
2020;51(3):607-615
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To prepare a PEOz modified single-walled carbon nanotube delivery system (PEOz-SWCNT) with the anti- tumor drug paclitaxel (PTX) as a model drug (PTX@PEOz-SWCNT) and evaluate its physical and chemical properties, in vitro drug release, biocompatibility, and in vitro antitumor effects. Methods: PEOz-SWCNT was synthesized by chemical coupling method, and the products were characterized by UV-Vis spectroscopy (UV-Vis) and infrared spectroscopy (FTIR). The particle size and Zeta potential of PEOz-SWCNT were measured. The drug-loaded complex PTX@PEOz-SWCNT was prepared and the loading efficiency and encapsulation efficiency were measured. The dialysis method was used for in vitro drug release. The safety of the application of PEOz-SWCNT was evaluated by in vitro hemolysis test. The MTT method was used to evaluate the biocompatibility of the material and the growth inhibition rate of the drug-loaded complex on MCF-7 cells. The uptake of Coumarin-6 (C6)-labeled vector in MCF-7 cells was examined by fluorescence inversion microscope. Results: The average particle size of PEOz-SWCNT was (219.8 ± 2.9) nm and the Zeta potential was (-35.23 ± 0.74) mV. The loading efficiency of PTX@PEOz-SWCNT was (38.19 ± 0.74) %, and the encapsulation efficiency was (94.38 ± 0.94)%. The drug release rate was significantly accelerated at pH 5.0, showing obvious pH responsiveness. There was no obvious hemolysis when the concentration of PEOz-SWCNT was below 0.4 mg/mL. The biocompatibility of PEOz-SWCNT on Hela cells was good, and the PTX@PEOz-SWCNT could significantly enhance the cell growth inhibition rate on MCF-7 cells. The in vitro antitumor activity test results showed that the cell uptake of the C6@PEOz-SWCNT was increased compared to C6@SWCNT. Conclusion: PTX@PEOz-SWCNT drug delivery system is promising in tumor-targeted drug delivery.
